Ann: Nasodine to be Launched in Fiji and South Pacific, page-2

The South Pacific is a relatively small market (around 2 million people), so why is this deal important?

1. It shows that there are more markets where we can introduce Nasodine without undue regulatory delays
2. It shows that market-savvy pharmaceutical partners see the potential in Nasodine
3. Like the Philippines agreement with SV More, Firebrick simply receives license fees with no marketing costs
4. It represents another market where people will enjoy the protective benefits of Nasodine

I should point out that this deal came about serendipitously because of our participation at the WONCA (World Congress of Family Doctors) conference in Singapore last year. A senior doctor from Fiji attended and she was so excited about Nasodine that she offered to help us get it on the market there. This is how the connection to Makans came about and ultimately led to the current agreement.

So, Nasodine is now available in USA, Singapore and the South Pacific, with the Philippines coming on board soon. More to come.